Background: Dupilumab was equally effective among all racial subgroups in clinical trials, but a direct comparison in daily practice is lacking. Objectives: To investigate the effectiveness of dupilumab in patients with atopic dermatitis (AD) in the Netherlands and Japan over 80 weeks of treatment. Methods: A longitudinal comparative cohort study was conducted in patients with AD who were treated with dupilumab in daily practice. We used linear mixed-effects models to determine changes over time. Results: We found statistically significant differences in sex, disease onset, body mass index and therapeutic history between Dutch (n = 208) and Japanese (n = 153) patients. The baseline Eczema Area and Severity Index (EASI) score was higher in Japanese patients (23·8 vs. 14·8), while baseline Patient-Reported Outcome Measures (PROMs) were higher in Dutch patients. EASI scores decreased quickly to a level indicating ‘mild disease’ (EASI < 7), and remained low in both countries. However, PROMs showed different trajectories with better scores in Japan. Conclusions: Dupilumab showed significant, comparable and sustained improvement of EASI scores in Japanese and Dutch patients. However, we found striking differences in the effect on PROMs between the countries, with a better outcome in Japanese patients.
|Number of pages||8|
|Journal||British Journal of Dermatology|
|Early online date||3 Mar 2021|
|Publication status||Published - 1 Sept 2021|
Bibliographical noteFunding Information:
ISAD Research Fellowship grant awarded to L.E.M. de Wijs. Funding sources
L.E.M.d.W.: ISAD Research Fellowship grant. R.F.T.F.: research grants from AbbVie, Eli Lilly, LEO Pharma, Maruho, Otsuka and Pfizer. E.R.A. and T.E.C.N.: none. D.H.: investigator for AbbVie, Galderma, LEO Pharma, MedImmune/AstraZeneca, Novartis and Sanofi/Regeneron; consultancies for Incyte, Janssen, LEO Pharma, Lilly, MedImmune/AstraZeneca, Novartis, Pfizer and Regeneron/Sanofi. Y.K.: lecture honoraria from Sanofi and Sysmex; research grants from AbbVie, Eli Lilly, LEO Pharma, Maruho, Otsuka, Pfizer and Sanofi. Conflicts of interest
© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.